Transition metal complexes are of increasing interest as photosensitizers in photodynamic
therapy (PDT) and, more recently, for photochemotherapy (PCT). In recent years, Ru (II) …

Ruthenium (II)-based coordination complexes have emerged as photosensitizers (PSs) for
photodynamic therapy (PDT) in oncology as well as antimicrobial indications and have great …

The increasing impact of cancer on worldwide mortality makes the research of novel
chemotherapeutic agents a current and challenging issue. In the recent years, transition …

Light, oxygen and photosensitizers (PSs) are the three separate elements that have been
applied in combination in the phototherapy of cancers in the past decades. Currently …

The utilization of photodynamic therapy (PDT) for the treatment of various types of cancer
has gained increasing attention over the last decades. Despite the clinical success of …

Photodynamic therapy (PDT) exploits light-activated compounds for therapeutic use. It relies
on a photosensitiser (PS) that is inactive in the absence of light. When irradiated, the PS …

Despite their past triumphs, platinum-based therapeutics remain limited by chemo-
resistance and severe side effects. As an alternative therapeutic modality which bypasses …

Photodynamic therapy (PDT) utilizes light-activated photosensitizers (PSs) to generate toxic
species for therapeutics. It has become an emerging solution for cancer treatment because …

The use of visible light to produce highly selective and potent drugs through photodynamic
therapy (PDT) holds much potential in the treatment of cancer. PDT agents can be designed …

Mounting evidence over the past 20 years suggests that photodynamic therapy (PDT), an
anticancer modality known mostly as a local treatment, has the capacity to invoke a systemic …